Therma Bright Inc. announced the completion and validation that its AcuVidTM COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant. The AcuVidTM /Delta variant study was completed at the company's Brazilian clinical study partner's lab location at the Federal University of Minas Gerais. The Delta B.1.617.2 variant has now become the dominant COVID-19 strain around the world; including the United States, United Kingdom, Europe, part of Africa and India. Out of an abundance of caution, the World Health Organization has urged fully vaccinated people to continue wearing masks due to this new variant strain. The Delta variant is becoming the fastest moving, most dominant COVID-19 strain globally; on June 24, Therma Bright and its partners announced and initiated the Delta variant study. The study focused on ensuring the Company's AcuVidTM COVID-19 Rapid Antigen Saliva Test would successfully perform and easily detect the ever-growing list of mutations from the original Wuhan SARS-CoV-2 Novel Coronavirus. To date, Therma Bright's AcuVidTM saliva test has successfully detected not only the original virus, but the P.1 and P.2 variants discovered in Brazil, the B.1.1.7 variant from the UK and now the highly-contagious Delta B.1.617.2 variant from India. Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.